Skip to main content
. 2025 Dec 8;13(12):1231. doi: 10.3390/vaccines13121231
AI Artificial intelligence
APC Antigen-presenting cell
CR Complete response
DC Dendritic cell
DCR Disease control rate
DoR Duration of response
ELISpot Enzyme-linked immunospot assay
GM-CSF Granulocyte-macrophage colony-stimulating factor
ICI Immune checkpoint inhibitor
LAG-3 Lymphocyte-activation gene 3
NED No evidence of disease
NSCLC Non-small cell lung cancer
ORR Objective response rate
OS Overall survival
PD Progressive disease
PD-1 Programmed cell death protein 1
PFS Progression-free survival
PR Partial response
SD Stable disease
STING Stimulator of interferon gene
TIM-3 T-cell immunoglobulin and mucin-domain containing 3
TIGIT T-cell immunoreceptor with Ig and ITIM domains
TLR Toll-like receptor
TME Tumor microenvironment
TNBC Triple-negative breast cancer